Welcome to our dedicated page for Generation Bio Co. SEC filings (Ticker: GBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Generation Bio Co. (NASDAQ: GBIO), a biotechnology company based in Cambridge, Massachusetts that focuses on T cell-driven autoimmune diseases. These regulatory documents provide detailed information on the company’s operations, financial condition, governance and transaction activity.
Generation Bio’s current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe quarterly financial results, including cash, cash equivalents and marketable securities, research and development expenses, general and administrative expenses and net loss. Other 8-Ks outline leadership changes, consulting arrangements with senior executives and lease-related matters.
A key 8-K filed on December 15, 2025 discloses an Agreement and Plan of Merger with XOMA Royalty Corporation and a wholly owned XOMA subsidiary. This filing details the structure of a tender offer for all outstanding shares of Generation Bio common stock, the subsequent merger in which Generation Bio would become a wholly owned subsidiary of XOMA Royalty, and the associated contingent value rights (CVRs). It also describes conditions to closing, treatment of equity awards, non-solicitation provisions, termination rights and the role of tender and support agreements with certain stockholders.
Through this filings page, users can access Generation Bio’s 8-Ks and other SEC documents as they become available from EDGAR. AI-powered tools on the platform can help summarize lengthy filings, highlight key terms in merger agreements, and surface information on topics such as transaction structure, listing status, compensation arrangements and financial reporting, enabling a more efficient review of GBIO’s regulatory disclosures.
Generation Bio Co. received an amended Schedule 13G from Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reporting their ownership of the company’s common stock. As of December 31, 2025, they beneficially owned 287,614 shares, representing 4.27% of Generation Bio’s outstanding common stock.
The filing states that certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds from these shares. The holders certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Generation Bio.
Generation Bio Co. received an amended Schedule 13G showing that Baselake Partners, LP, Baselake Management, LLC and David Paolella now report beneficial ownership of 0 shares of Generation Bio common stock, or 0% of the class.
The filing confirms they have no sole or shared voting or dispositive power over any Generation Bio shares and that they own 5 percent or less of the company’s common stock. The certifying parties state the securities were not acquired or held with the purpose or effect of changing or influencing control of Generation Bio.
Generation Bio Co. became a wholly owned subsidiary of XOMA Royalty Corporation after a merger completed on February 9, 2026. Under the merger agreement, each tendered Generation Bio common share was exchanged for $4.2913 in cash per share plus one non-tradeable contingent value right (CVR) per share.
Each CVR represents the right to receive potential future cash payments, with an estimated maximum contingent consideration of $25.01 per CVR, subject to specified terms and conditions. In connection with this transaction, Atlas Venture–affiliated funds that were 10% owners reported disposition of 711,193, 116,693 and 60 Generation Bio common shares, and reported owning zero shares afterward.
Generation Bio Co. director Catherine Stehman-Breen reported the disposition of her equity in connection with the company’s sale to XOMA Royalty Corporation. She tendered 4,752 shares of common stock, which were exchanged for $4.2913 in cash per share plus one non-tradeable contingent value right (CVR) per share, with an estimated maximum contingent cash payment of $25.01 per CVR. Following completion of the tender offer, XRA 7 Corp. merged into Generation Bio on February 9, 2026, making it a wholly owned subsidiary of XOMA Royalty. Her in-the-money stock options vested, were cancelled, and converted into cash based on the spread to the cash amount, while out-of-the-money options were cancelled for no consideration, leaving her with 0 shares and 0 options reported as beneficially owned.
Generation Bio Co.$4.2913 per share in cash plus one non-tradeable contingent value right (CVR) per share, with an estimated maximum contingent cash payment of up to
Rowland Charles A Jr reported disposition of 53,475 shares of common stock and now holds zero shares directly. All reported stock options to purchase common stock were also disposed of, leaving no derivative securities beneficially owned. Options with exercise prices below the cash amount became fully vested and were cancelled in exchange for cash, while those with exercise prices at or above the cash amount were cancelled for no consideration.
Generation Bio Co. has been acquired by XOMA Royalty Corporation, and a director is reporting related share and option changes. Under the merger agreement, each share of Generation Bio common stock tendered before the offer deadline was exchanged for $4.2913 in cash per share plus one non-tradeable contingent value right (CVR), with an estimated maximum contingent cash consideration of $25.01 per CVR.
After the tender offer, XOMA’s subsidiary merged into Generation Bio on February 9, 2026, making Generation Bio a wholly owned subsidiary. Entities affiliated with director Jason P. Rhodes, including Atlas Venture funds, had their indirect holdings in Generation Bio common stock converted into the cash-and-CVR consideration, with Rhodes disclaiming beneficial ownership except for any pecuniary interest. In addition, his outstanding stock options were either cashed out if in-the-money or cancelled for no consideration if the exercise price was at or above the cash amount.
Generation Bio director Anthony G. Quinn reported the cash-out of his equity as part of the company’s merger with XOMA Royalty Corporation. Common shares of Generation Bio were exchanged for a cash price of $4.2913 per share plus one non-tradeable contingent value right (CVR) per share, with each CVR having an estimated maximum contingent consideration of $25.01. Quinn reported 29,928 shares of common stock held directly and 7,283 shares held indirectly through the Quinn Family Irrevocable Trust of 2021. All reported stock options were cancelled at the merger effective time: in-the-money options were converted into a cash payment based on the excess of the cash amount over the exercise price, while options with an exercise price at or above the cash amount were cancelled for no consideration.
Generation Bio Co. has been acquired by XOMA Royalty Corporation under a Merger Agreement dated December 15, 2025. Common shareholders who tendered their shares received
Generation Bio Co. director Geoff McDonough reported changes in his holdings following the completion of a merger with XOMA Royalty Corporation. Common shares of Generation Bio were exchanged for
The Form 4 shows 138,492 shares of common stock held directly and additional shares held indirectly through the McDonough Family 2018 and 2020 Irrevocable Trusts being impacted by the transaction. It also reports that, under the merger agreement, stock options with exercise prices at or above the cash amount of
FAQ
What is the current stock price of Generation Bio Co. (GBIO)?
What is the market cap of Generation Bio Co. (GBIO)?
